Considering the contribution of the SPP1 pathway to unfavourable overall survival for NSCLC patients, therapy targeting SPP1‐related cell–cell interactions may provide insights into the inhibition of the bone metastasis of NSCLC. The gene discussed is SPP1; the disease is non-small cell lung carcinoma.